Trial Profile
A Phase 1, Adaptive, Single and Multiple Ascending Dose Study of EMA401 Sodium Salt Administered Orally in Healthy, Adult Males to Determine the Maximum Tolerated Dose and Pharmacokinetic Profiles
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Olodanrigan (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions
- Sponsors Spinifex Pharmaceuticals
- 23 Jan 2015 Status changed from recruiting to completed as reported by Australian New Zealand Clinical Trials Registry.
- 11 Sep 2014 New trial record